We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Growth Seen for European POC Coagulation Testing

By HospiMedica staff writers
Posted on 15 Dec 2003
The point-of-care (POC) testing market in Europe will grow from 140 million euros in 2003 to more than 350 million euros in 2009, according to a new analysis from international consultants Frost & Sullivan (London, UK). More...
This figure includes near-testing and self-testing devices. The growth is being fostered by the clinical results and the lower costs of an increasing number of outpatient anticoagulation clinics.

POC coagulation analyzers are gaining preference in the critical care, surgery, and home testing environments, since they provide rapid and accurate information for improved patient monitoring. Coagulation testing looks at endpoint measurements between bleeding and clotting, and the new technologic developments are expected to allow a comprehensive assessment of the complex interactions between various blood clotting factors.

"The biggest advantage of POC testing is the decrease in turn-around time because most POC analyses are performed on whole blood, minimizing any transport and logistic handovers that normally occur within laboratory testing,” explained Shree Viswadia, a research analyst with Frost & Sullivan.

Market concerns include slow implementation of insurance reimbursement and the development of new thrombin inhibitor drugs that could gradually eliminate the need for routine testing. Nonetheless, POC testing is finding increasing acceptance across Europe, with Germany, Italy, and the United Kingdom having the largest number of users.




Related Links:
Frost & Sullivan >>

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The automated multiplex PCR assay runs on the BioFire Spotfire Vaginitis System, bringing molecular vaginitis testing to the point of care (Photo courtesy of bioMérieux)

Molecular Vaginitis Panel Gains FDA Clearance and CLIA Waiver for Point-of-Care Use

Vaginitis affects most women at least once in their lifetime and can cause painful, disruptive symptoms. Common causes include bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis, reflecting... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: The CE-marked software IVD combines digital histopathology and clinicopathological data to generate a prognostic classification (Image Credit: Shutterstock)

Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer

In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.